Abstract
Manufactured tobacco contains over 4, 000 toxic substances, but only a few exert adverse cardiovascular effects. Nicotine and its metabolites, carbon monoxide, thiocyanate and some aromatic amines play a strong, although different, role to determine cardiovascular damage. Of these substances, however, nicotine, acting by the double mechanism of addiction and receptor-binding, and carbon monoxide by increasing the production of carboxyhemoglobin and hypoxia, are the main determinants of the damage.
The development of the alterations of heart and blood vessels follows a typical way, initially consisting of functional responses that become irreversible pathological lesions at the time.
Myocardium and endothelial cells are the targets where cigarette smoking exerts its effects. The first displays functional and pathological disorders primarily related to ischemic heart disease, cardiomyopathy, including experimental cardiomyopathy from smoking, and heart failure, while the second should be interpreted as a structure, which shows early alterations caused by smoking as clearly evident, repeatable and typically depending on smoking toxicity.
Cardiovascular damage has a functional onset, which, at the time, leads to irreversible morphological damage of myocardial and endothelial cells.
Keywords: Tobacco toxics, myocardium, endothelium, functional damage, cell damage.
Current Pharmaceutical Design
Title:Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Volume: 21 Issue: 30
Author(s): Aurelio Leone
Affiliation:
Keywords: Tobacco toxics, myocardium, endothelium, functional damage, cell damage.
Abstract: Manufactured tobacco contains over 4, 000 toxic substances, but only a few exert adverse cardiovascular effects. Nicotine and its metabolites, carbon monoxide, thiocyanate and some aromatic amines play a strong, although different, role to determine cardiovascular damage. Of these substances, however, nicotine, acting by the double mechanism of addiction and receptor-binding, and carbon monoxide by increasing the production of carboxyhemoglobin and hypoxia, are the main determinants of the damage.
The development of the alterations of heart and blood vessels follows a typical way, initially consisting of functional responses that become irreversible pathological lesions at the time.
Myocardium and endothelial cells are the targets where cigarette smoking exerts its effects. The first displays functional and pathological disorders primarily related to ischemic heart disease, cardiomyopathy, including experimental cardiomyopathy from smoking, and heart failure, while the second should be interpreted as a structure, which shows early alterations caused by smoking as clearly evident, repeatable and typically depending on smoking toxicity.
Cardiovascular damage has a functional onset, which, at the time, leads to irreversible morphological damage of myocardial and endothelial cells.
Export Options
About this article
Cite this article as:
Leone Aurelio, Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage, Current Pharmaceutical Design 2015; 21 (30) . https://dx.doi.org/10.2174/1381612821666150803145149
DOI https://dx.doi.org/10.2174/1381612821666150803145149 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Outcomes of Patients with Chronic Heart Failure and Iron Deficiency Treated with Intravenous Iron: A Meta-analysis
Cardiovascular & Hematological Disorders-Drug Targets A Mitochondrial Approach to Cardiovascular Risk and Disease
Current Pharmaceutical Design Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Mesenchymal Stromal Cells: A Promising Cell Source for the Treatment of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls
Current Gene Therapy The Role of Beta-Blocker in Heart Failure in Adults with Congenital Heart Disease
Reviews on Recent Clinical Trials Monitoring Cardiac Function During Idebenone Therapy in Friedreich's Ataxia
Current Pharmaceutical Design Stage B: What is the Evidence for Treatment of Asymptomatic Left Ventricular Dysfunction?
Current Cardiology Reviews Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia
Current Neurovascular Research The Molecular Concept of Atheromatous Plaques
Current Drug Targets Surgical Ventricular Restoration to Reverse Left Ventricular Remodeling
Current Cardiology Reviews Cardiac Toxicity of Antineoplastic Anthracyclines
Current Medicinal Chemistry - Anti-Cancer Agents The Quest for Novel Biomarkers in Early Diagnosis of Diabetic Neuropathy
Current Proteomics Can Lipoprotein-associated Phospholipase A<sub>2</sub> be Used as a Predictor of Long-term Outcome in Patients with Acute Coronary Syndrome?
Current Cardiology Reviews Evaluation of Gene and Cell-Based Therapies for Cardiac Regeneration
Current Stem Cell Research & Therapy Gene Therapy Approaches for Cardiovascular Diseases
Current Gene Therapy Mass Spectrometry Data Analysis in the Proteomics Era
Current Bioinformatics Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research